Rational Design of a New RXR Agonist Scaffold Enabling Single-Subtype Preference for RXRα, RXRβ, and RXRγ-Reference-Cited by-同舟云学术

Rational Design of a New RXR Agonist Scaffold Enabling Single-Subtype Preference for RXRα, RXRβ, and RXRγ

Published:2022-12-19 Issue:1 Volume:66 Page:333-344
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Adouvi Gustave¹,Isigkeit Laura¹^ORCID,López-García Úrsula²^ORCID,Chaikuad Apirat¹^ORCID,Marschner Julian A.²,Schubert-Zsilavecz Manfred¹,Merk Daniel¹²^ORCID

Affiliation:

1. Institute of Pharmaceutical Chemistry, Goethe University Frankfurt, 60438 Frankfurt, Germany

2. Department of Pharmacy, Ludwig-Maximilians-Universität München,81377 Munich, Germany

Funder

Deutsche Forschungsgemeinschaft

Friedrich Naumann Stiftung

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.2c01266

Reference44 articles.

1. International Union of Pharmacology. LXIII. Retinoid X Receptors

2. Retinoid X Receptor: Cellular and Biochemical Roles of Nuclear Receptor with a Focus on Neuropathological Involvement

3. Therapeutic modulation of retinoid X receptors – SAR and therapeutic potential of RXR ligands and recent patents

4. Nuclear Receptors, RXR, and the Big Bang

5. A partial agonist for retinoid X receptor mitigates experimental colitis

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rational design and virtual screening identify mimetics of the RXR agonist valerenic acid;ChemMedChem;2024-01-31

2. Structure-Guided Design of a Highly Potent Partial RXR Agonist with Superior Physicochemical Properties;Journal of Medicinal Chemistry;2024-01-18

3. Structural Fusion of Natural and Synthetic Ligand Features Boosts RXR Agonist Potency;Journal of Medicinal Chemistry;2023-12-08

4. Structural Modification of the Natural Product Valerenic Acid Tunes RXR Homodimer Agonism;ChemMedChem;2023-09-25

5. Opportunities and challenges in targeting orphan nuclear receptors;Chemical Communications;2023